意大利Okairos www.okairos.com 

Okairos公司有一個(gè)好的開(kāi)端--自從從默沙東公司剝離出來(lái)后，它已得到來(lái)自BioMedlnvest、勃林格殷格翰（Boehringer Ingelheim）公司風(fēng)險(xiǎn)基金、LSP、諾華（Novartis）公司風(fēng)險(xiǎn)基金和Versant Ventures公司的支持。其疫苗技術(shù)在預(yù)防呼吸道合胞病毒和流感病毒方面也具有很大的潛力。目前已有許多生物技術(shù)公司在專(zhuān)注于丙型肝炎疫苗的開(kāi)發(fā)
2013年GSK 2.5億歐元收購(gòu)瑞士疫苗平臺(tái)Okairos AG 
 

We are a clinical-stage biopharmaceutical company spun out from Merck in 2007. Our headquarters are in Basel and we have laboratories in Rome and Naples.

Our founders, Riccardo Cortese and his team, were also the founders of Istituto di Ricerche di Biologia Molecolare (IRBM), which later became a subsidiary of Merck Inc. While at IRBM, they made significant contributions to the field of infectious diseases, including elucidation of the mechanism of action of the hepatitis C protease and polymerase enzymes, and discovery of the HIV fusion inhibitor ISENTRESS®.

Today we are developing genetic vaccines for major infectious diseases, including hepatitis C, malaria, HIV, respiratory syncytial virus and influenza. We are also pursuing therapeutic vaccines to treat cancer.

Our approach is centred on exploiting our novel, proprietary and highly potent, replication-incompetent adenovirus vectors. We have derived these vectors from strains isolated from non-human primates, which prevents them from being recognised by pre-existing neutralising antibodies in humans. This ground-breaking approach overcomes the major limitation of first-generation vectors, opening the door to the development of important new vaccines.

“We now understand that the spectacular past successes of vaccines were based on the protective action of antibodies. Unfortunately, for chronic infectious diseases and possibly cancer, vaccines exclusively based on the humoral response are largely ineffective. We believe that, during the next decade, a new generation of T-cell based vaccines will become the major medical contribution in the fight against infectious disease.”

Riccardo Cortese, Chief Executive Officer, Okairos